Literature DB >> 27482290

Pricing of innovative drugs: correlation between incremental cost and survival gain in four countries.

Daniele Mengato1, Andrea Messori2.   

Abstract

Year:  2016        PMID： 27482290      PMCID： PMC4952021          DOI： 10.1177/1758834016644465

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


× No keyword cloud information.
  8 in total

1.  Value-Based Cancer Care.

Authors:  Robert C Young
Journal:  N Engl J Med       Date:  2015-11-18       Impact factor: 91.245

Review 2.  The NICE cost-effectiveness threshold: what it is and what that means.

Authors:  Christopher McCabe; Karl Claxton; Anthony J Culyer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Analysis of Medicine Prices in New Zealand and 16 European Countries.

Authors:  Sabine Vogler; Kate Kilpatrick; Zaheer-Ud-Din Babar
Journal:  Value Health       Date:  2015-04-04       Impact factor: 5.725

4.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Courtney Tyne; Douglas W Blayney; Diane Blum; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

5.  Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer.

Authors:  Takanori Tsuchiya; Takashi Fukuda; Masashi Furuiye; Koichi Kawabuchi
Journal:  Lung Cancer       Date:  2011-05-13       Impact factor: 5.705

6.  Pharmaceutical Policy Reform--Balancing Affordability with Incentives for Innovation.

Authors:  Rena M Conti; Meredith B Rosenthal
Journal:  N Engl J Med       Date:  2016-02-25       Impact factor: 91.245

7.  Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial.

Authors:  T Shiroiwa; T Fukuda; K Shimozuma
Journal:  Br J Cancer       Date:  2011-09-29       Impact factor: 7.640

8.  Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan.

Authors:  Takeshi Ebara; Tatsuya Ohno; Takashi Nakano
Journal:  Daru       Date:  2013-05-25       Impact factor: 3.117
  8 in total
  1 in total

1.  Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.

Authors:  Etsuko Satoh; Yasutsuna Sasaki; Ryotaro Ohkuma; Takehiro Takahashi; Yutaro Kubota; Hiroo Ishida; Kazuyuki Hamada; Yuji Kiuchi; Takuya Tsunoda
Journal:  Cancer Sci       Date:  2018-11-27       Impact factor: 6.716
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.